Regulated Pricing Decisions and Diagnostic Test Choices in Personalized Medicine: Navigating the Implications Within Legal Frameworks
The findings underscore the importance of legal frameworks in the personalized medicine industry. The absence of the government's regulated pricing incentivizes collaborations with high-level diagnostic firms, enhancing consumer surplus and social welfare. However, government intervention in pricing makes such decisions contingent on specific conditions, requiring nuanced regulatory policies that balance the interests of patients, manufacturers, and diagnostic firms.
Authors
- Zhengzong Huang (ORCID: https://orcid.org/0000-0003-1227-890X)
- Zehua Feng (ORCID: https://orcid.org/0000-0002-6838-0893)
- Zibin Cui
- Xiangdong Liu (ORCID: https://orcid.org/0009-0004-0997-9304)
Institutions
- Guangdong University of Technology (CN)
- Shenzhen Technology University (CN)
- Macao Polytechnic University (MO)
Publication Details
- Journal
- Risk Management and Healthcare Policy
- Published
- 2024-11-01
- DOI
- https://doi.org/10.2147/rmhp.s475929
- Citations
- 1
- Primary Topic
- Pharmaceutical industry and healthcare
- Type
- article
- Field-Weighted Citation Impact
- 0.47
Funders
- Shenzhen Technology University
- Ministry of Education of the People's Republic of China